KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) shares surged 18.20% in pre-market trading on Monday, July 7, 2025, hitting $14.16 after FDA approval of HAE candidate. This jump follows a previous closing price of $11.98 from the prior trading day.
KalVista Pharmaceuticals, Inc. (KALV) announced FDA approval of EKTERLY, a novel plasma kallikrein inhibitor, for treating acute hereditary angioedema attacks in patients aged 12 and older. EKTERLY is the first and only oral on-demand treatment for hereditary angioedema.
Prior to EKTERLY, all U.S. on-demand treatments required intravenous or subcutaneous administration, creating a significant treatment burden. The efficacy and safety of EKTERLY were demonstrated in KalVista Pharmaceuticals’ phase 3 KONFIDENT clinical trial, the largest ever conducted in hereditary angioedema.
